GLP-1 drugs appear safe for inflammatory bowel disease patients, with 7 kg weight loss and no increased flare risk | Research

The takeaway

Meta-analysis of 10 studies (10,362 IBD patients) shows GLP-1 drugs are safe in IBD with no increased risk of corticosteroids, treatment escalation, or surgery, while achieving 7.33 kg weight loss and 6.67% body weight reduction.

Safe in IBD + 7.33 kg weight loss
GLP-1 drugs showed no increased IBD flare or treatment escalation risk while achieving consistent weight loss (I²=0%) in 10,362 patients

What the researchers found

No increased risk: corticosteroids OR 0.93, treatment escalation OR 0.70, surgery OR 0.32. Weight loss: -7.33 kg (I²=0%), -6.67% body weight (I²=0%), BMI -2.48 (I²=0%). Flare incidence: 14%. 10,362 patients across 10 studies.

Why it matters

Clinicians have been hesitant to prescribe GLP-1 drugs to IBD patients due to overlapping GI symptoms. This is the most comprehensive safety analysis to date, providing reassurance that these drugs can be used safely.

How the study worked

Systematic review through June 2025. 10 observational studies, 10,362 IBD patients (3,479 GLP-1RA, 6,883 controls). Pooled ORs and mean changes.

What this study cannot tell us

All observational studies. Heterogeneity high for surgery outcome (I²=92.5%). Most studies short-term. Cannot exclude long-term risks. Selection bias possible.

How to read the evidence

Meta-analysis of 10 observational studies. Large patient pool. Zero heterogeneity for weight outcomes strengthens confidence. Safety findings reassuring but observational.

When this study was published

Published in 2025; literature through June 2025.

The bigger picture

With obesity increasingly common in IBD, GLP-1 drugs fill a critical need. This safety data, combined with GLP-1 drugs' known anti-inflammatory properties, suggests they may not just be safe but potentially beneficial for IBD patients.

Questions still open

Could GLP-1 drugs' anti-inflammatory effects actually improve IBD outcomes?
Should prospective RCTs study GLP-1 drugs specifically in IBD?
Are certain IBD subtypes (Crohn's vs UC) more suitable for GLP-1 therapy?

Common questions

Is it safe to take GLP-1 drugs with Crohn's disease or ulcerative colitis?

This large analysis of over 10,000 IBD patients found GLP-1 drugs did not increase the risk of disease flares, need for steroids, treatment escalation, or surgery. Patients also lost significant weight. The drugs appear safe, though close monitoring is still recommended.

Won't the stomach side effects of GLP-1 drugs make IBD worse?

This was the main concern, but the data is reassuring. Despite the overlap between GLP-1 side effects (nausea, GI upset) and IBD symptoms, patients on GLP-1 drugs did not have worse IBD outcomes. The drugs' anti-inflammatory properties may actually provide some protection.

Read the original research

Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.

Journal of Crohn's & colitis, 19(12)

View on PubMed ↗Publisher’s paper ↗

Citation

Siranart, Noppachai; Nakaphan, Pannathorn; Pajareya, Patavee; Laohasurayotin, Khamik. (2025). Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.. Journal of Crohn's & colitis, 19(12). https://doi.org/10.1093/ecco-jcc/jjaf193